Stockholders' Equity (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended
	Sep. 12, 2019	Jan. 07, 2019	Aug. 31, 2019	Oct. 31, 2019	Jul. 31, 2019
Common stock payable, Shares				296,793
Common stock payable, Amount				$ 215,793
Common stock issued				286,377
Common stock issued for conversion debt, Shares				1,164,190
Common stock issued for conversion debt, Value				$ 1,736,900
Cancellation of common stock	20,375,900
Common stock, shares outstanding				44,336,023	62,290,940
Regentys
LOI Terms		Pursuant to the Company’s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161 shares of Regentys common stock. As of October 31, 2019, Regentys had a total of 18,623,278 shares of common stock and 2,793,192 Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest.
Olaregen
LOI Terms		Pursuant to the Company’s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common stock. In May 2019, the Company issued 4,000,000 shares of common stock and a $2 million note payable for the acquisition of 592,683 shares of Series A Preferred Stock of Olaregen pursuant to a Stock Purchase Agreement entered into January 14, 2019 subject to the approval of the Board of Directors of Olaregen and consummated on May 10, 2019. On August 16, 2019, the Company entered into a Share Exchange Agreement to purchase an additional 900,000 shares of common stock in Olaregen from other shareholders of Olaregen in exchange for 1,905,912 shares of Generex common stock and 476,478 shares of Antigen common stock. In September 2019, the Company converted all of the Series A Preferred Stock of Olaregen into common stock of Olaregen.
Common stock, shares outstanding				6,236,390
Preferred stock, shares outstanding				0
Non-controlling interest				1,461,075
Percentage of non-controlling interest				23.43%
Medisource
Common stock issued for acquisition			400,000
Stock Price			$ 2.50
Pantheon [Member]
Common stock issued for acquisition			560,000
Stock Price			$ 2.50